SCHEMBL30272465

CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)O

nearest known ligand 0.58

Predicted protein targets (top 15)

	gene	UniProt	supporting neighbours	confidence
▸	CXCR4	P61073	4/20	0.58

▸	GLP1R	P43220	6/20	0.56

▸	CCKBR	P32239	4/20	0.56

▸	CALCR	P30988	4/20	0.54

▸	NPY1R	P25929	1/20	0.54

▸	NPY2R	P49146	1/20	0.54

▸	NPY4R	P50391	1/20	0.54

▸	NPY5R	Q15761	1/20	0.54

▸	HCRTR1	O43613	1/20	0.53

▸	HCRTR2	O43614	1/20	0.53

▸	NMBR	P28336	2/20	0.53

▸	GRPR	P30550	2/20	0.53

▸	GCGR	P47871	1/20	0.51

▸	GIPR	P48546	1/20	0.51

▸	F2	P00734	1/20	0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29416120	0.96	GLP1R (0.58)	CXCR4GLP1RCCKBRCALCRHCRTR1
SCHEMBL29812703	0.90	GLP1R (0.63)	CXCR4GLP1RCCKBRCALCRNPY1R
SCHEMBL29706175	0.89	GLP1R (0.64)	CXCR4GLP1RCCKBRCALCRNPY1R
SCHEMBL31452907	0.87	CAPN1 (0.58)	CXCR4GLP1RCCKBRNPY1RNPY2R
SCHEMBL29812659	0.86	GLP1R (0.70)	GLP1RCCKBRCALCRNPY1RNPY2R
SCHEMBL30527917	0.86	GLP1R (0.66)	CXCR4GLP1RCCKBRCALCRHCRTR1
SCHEMBL31182867	0.85	CALCR (0.63)	CXCR4GLP1RCCKBRCALCRNPY1R
SCHEMBL29695449	0.85	GLP1R (0.58)	CXCR4GLP1RCCKBRCALCRNMBR
SCHEMBL38662212	0.85	CCKBR (0.54)	CXCR4GLP1RCCKBRCALCRNPY1R
SCHEMBL31307904	0.84	CXCR4 (0.68)	CXCR4GLP1RCALCRNPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-11628202-B2	Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia	NYMOX CORPORATION (CA)	2023-04-18	—	—	US	disclosed